Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2015

Open Access 01-12-2015 | Research

Oral administration of cytosolic PLA2 inhibitor arachidonyl trifluoromethyl ketone ameliorates cauda equina compression injury in rats

Authors: Mushfiquddin Khan, Anandakumar Shunmugavel, Tajinder S Dhammu, Fumiyo Matsuda, Avtar K Singh, Inderjit Singh

Published in: Journal of Neuroinflammation | Issue 1/2015

Login to get access

Abstract

Background

Phospholipase A2 (PLA2)-derived proinflammatory lipid mediators such as prostaglandin E2 (PGE2), leukotrienes B4 (LTB4), lysophosphatidylcholine (LPC), and free fatty acids (FFA) are implicated in spinal cord injury (SCI) pathologies. Reducing the levels of these injurious bioactive lipid mediators is reported to ameliorate SCI. However, the specific role of the group IVA isoform of PLA2 cytosolic PLA2 (cPLA2) in lumbar spinal canal stenosis (LSS) due to cauda equina compression (CEC) injury is not clear. In this study, we investigated the role of cPLA2 in a rat model of CEC using a non-toxic cPLA2-preferential inhibitor, arachidonyl trifluoromethyl ketone (ATK).

Methods

LSS was induced in adult female rats by CEC procedure using silicone blocks within the epidural spaces of L4 to L6 vertebrae. cPLA2 inhibitor ATK (7.5 mg/kg) was administered by oral gavage at 2 h following the CEC. cPLA2-derived injurious lipid mediators and the expression/activity of cPLA2, 5-lipoxygenase (5-LOX), and cyclooxygenase-2 (COX-2) were assessed. ATK-treated (CEC + ATK) were compared with vehicle-treated (CEC + VEH) animals in terms of myelin levels, pain threshold, and motor function.

Results

ATK treatment of CEC animals reduced the phosphorylation of cPLA2 (pcPLA2) determined by Western blot, improved locomotor function evaluated by rotarod task, and reduced pain threshold evaluated by mechanical hyperalgesia method. Levels of FFA and LPC, along with PGE2 and LTB4, were reduced in CEC + ATK compared with CEC + VEH group. However, ATK treatment reduced neither the activity/expression of 5-LOX nor the expression of COX-2 in CEC + VEH animals. Increased cPLA2 activity in the spinal cord from CEC + VEH animals correlated well with decreased spinal cord as well as cauda equina fiber myelin levels, which were restored after ATK treatment.

Conclusion

The data indicate that cPLA2 activity plays a significant role in tissue injury and pain after LSS. Reducing the levels of proinflammatory and tissue damaging eicosanoids and the deleterious lipid mediator LPC shows therapeutic potential. ATK inhibits cPLA2 activity, thereby decreasing the levels of injurious lipid mediators, reducing pain, improving functional deficits, and conferring protection against LSS injury. Thus, it shows potential for preclinical evaluation in LSS.
Literature
1.
Katz JN. Lumbar disc disorders and low-back pain: socioeconomic factors and consequences. J Bone Joint Surg Am. 2006;88 Suppl 2:21–4.CrossRefPubMed
2.
Kalff R, Ewald C, Waschke A, Gobisch L, Hopf C. Degenerative lumbar spinal stenosis in older people: current treatment options. Dtsch Arztebl Int. 2013;110:613–23. quiz 624.PubMedCentralPubMed
3.
Tran DQ, Duong S, Finlayson RJ. Lumbar spinal stenosis: a brief review of the nonsurgical management. Can J Anaesth. 2010;57:694–703.CrossRefPubMed
4.
Siebert E, Pruss H, Klingebiel R, Failli V, Einhaupl KM, Schwab JM. Lumbar spinal stenosis: syndrome, diagnostics and treatment. Nat Rev Neurol. 2009;5:392–403.CrossRefPubMed
5.
Maihofner C, Nickel FT, Seifert F. [Neuropathic pain and neuroplasticity in functional imaging studies]. Schmerz. 2010;24:137–45.CrossRefPubMed
6.
Tsuda M, Inoue K, Salter MW. Neuropathic pain and spinal microglia: a big problem from molecules in “small” glia. Trends Neurosci. 2005;28:101–7.CrossRefPubMed
7.
Linkous A, Yazlovitskaya E. Cytosolic phospholipase A2 as a mediator of disease pathogenesis. Cell Microbiol. 2010;12:1369–77.CrossRefPubMed
8.
Farooqui AA, Ong WY, Horrocks LA. Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacol Rev. 2006;58:591–620.CrossRefPubMed
9.
10.
Leoncini G, Bruzzese D, Signorello MG. Activation of p38 MAPKinase/cPLA2 pathway in homocysteine-treated platelets. J Thromb Haemost. 2006;4:209–16.CrossRefPubMed
11.
Lin LL, Wartmann M, Lin AY, Knopf JL, Seth A, Davis RJ. cPLA2 is phosphorylated and activated by MAP kinase. Cell. 1993;72:269–78.CrossRefPubMed
12.
Obata K, Yamanaka H, Kobayashi K, Dai Y, Mizushima T, Katsura H, et al. Role of mitogen-activated protein kinase activation in injured and intact primary afferent neurons for mechanical and heat hypersensitivity after spinal nerve ligation. J Neurosci. 2004;24:10211–22.CrossRefPubMed
13.
Liu NK, Deng LX, Zhang YP, Lu QB, Wang XF, Hu JG, et al. Cytosolic phospholipase A2 protein as a novel therapeutic target for spinal cord injury. Ann Neurol. 2014;75:644–58.CrossRefPubMedCentralPubMed
14.
15.
Shimizu T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol. 2009;49:123–50.CrossRefPubMed
16.
Kita Y, Ohto T, Uozumi N, Shimizu T. Biochemical properties and pathophysiological roles of cytosolic phospholipase A2s. Biochim Biophys Acta. 2006;1761:1317–22.CrossRefPubMed
17.
Peters-Golden M, McNish RW. Redistribution of 5-lipoxygenase and cytosolic phospholipase A2 to the nuclear fraction upon macrophage activation. Biochem Biophys Res Commun. 1993;196:147–53.CrossRefPubMed
18.
Phillis JW, Horrocks LA, Farooqui AA. Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Res Rev. 2006;52:201–43.CrossRefPubMed
19.
Grewal S, Herbert SP, Ponnambalam S, Walker JH. Cytosolic phospholipase A2-alpha and cyclooxygenase-2 localize to intracellular membranes of EA.hy.926 endothelial cells that are distinct from the endoplasmic reticulum and the Golgi apparatus. FEBS J. 2005;272:1278–90.CrossRefPubMed
20.
Herbert SP, Odell AF, Ponnambalam S, Walker JH. The confluence-dependent interaction of cytosolic phospholipase A2-alpha with annexin A1 regulates endothelial cell prostaglandin E2 generation. J Biol Chem. 2007;282:34468–78.CrossRefPubMed
21.
Golfman LS, Haughey NJ, Wong JT, Jiang JY, Lee D, Geiger JD, et al. Lysophosphatidylcholine induces arachidonic acid release and calcium overload in cardiac myoblastic H9c2 cells. J Lipid Res. 1999;40:1818–26.PubMed
22.
Murphy EJ, Behrmann D, Bates CM, Horrocks LA. Lipid alterations following impact spinal cord injury in the rat. Mol Chem Neuropathol. 1994;23:13–26.CrossRefPubMed
23.
Liu NK, Zhang YP, Titsworth WL, Jiang X, Han S, Lu PH, et al. A novel role of phospholipase A2 in mediating spinal cord secondary injury. Ann Neurol. 2006;59:606–19.CrossRefPubMed
24.
Huang W, Bhavsar A, Ward RE, Hall JC, Priestley JV, Michael-Titus AT. Arachidonyl trifluoromethyl ketone is neuroprotective after spinal cord injury. J Neurotrauma. 2009;26:1429–34.CrossRefPubMed
25.
Amar AP, Levy ML. Pathogenesis and pharmacological strategies for mitigating secondary damage in acute spinal cord injury. Neurosurgery. 1999;44:1027–39. discussion 1039–1040.CrossRefPubMed
26.
Kuba T, Hunter D, Zhou L, Jenab S, Quinones-Jenab V. Endogenous gonadal hormones regulate females’ behavioral responses to formalin through prostaglandin E2 release. Ethn Dis. 2010;20:S1-55-59.
27.
Takeda K, Sawamura S, Tamai H, Sekiyama H, Hanaoka K. Role for cyclooxygenase 2 in the development and maintenance of neuropathic pain and spinal glial activation. Anesthesiology. 2005;103:837–44.CrossRefPubMed
28.
Myers RR, Campana WM, Shubayev VI. The role of neuroinflammation in neuropathic pain: mechanisms and therapeutic targets. Drug Discov Today. 2006;11:8–20.CrossRefPubMed
29.
Kawakami M, Matsumoto T, Hashizume H, Kuribayashi K, Chubinskaya S, Yoshida M. Osteogenic protein-1 (osteogenic protein-1/bone morphogenetic protein-7) inhibits degeneration and pain-related behavior induced by chronically compressed nucleus pulposus in the rat. Spine (Phila Pa 1976). 2005;30:1933–9.CrossRef
30.
Costa B, Conti S, Giagnoni G, Colleoni M. Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems. Br J Pharmacol. 2002;137:413–20.CrossRefPubMedCentralPubMed
31.
Nicol GD, Klingberg DK, Vasko MR. Prostaglandin E2 increases calcium conductance and stimulates release of substance P in avian sensory neurons. J Neurosci. 1992;12:1917–27.PubMed
32.
O’Rielly DD, Loomis CW. Spinal nerve ligation-induced activation of nuclear factor kappaB is facilitated by prostaglandins in the affected spinal cord and is a critical step in the development of mechanical allodynia. Neuroscience. 2008;155:902–13.CrossRefPubMed
33.
Southan GJ, Szabo C. Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Biochem Pharmacol. 1996;51:383–94.CrossRefPubMed
34.
Mollace V, Muscoli C, Masini E, Cuzzocrea S, Salvemini D. Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol Rev. 2005;57:217–52.CrossRefPubMed
35.
Tanabe M, Nagatani Y, Saitoh K, Takasu K, Ono H. Pharmacological assessments of nitric oxide synthase isoforms and downstream diversity of NO signaling in the maintenance of thermal and mechanical hypersensitivity after peripheral nerve injury in mice. Neuropharmacology. 2009;56:702–8.CrossRefPubMed
36.
Borda E, Furlan C, Orman B, Reina S, Sterin-Borda L. Nitric oxide synthase and PGE2 reciprocal interactions in rat dental pulp: cholinoceptor modulation. J Endod. 2007;33:142–7.CrossRefPubMed
37.
Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A, Poole S, et al. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature. 2001;410:471–5.CrossRefPubMed
38.
Riendeau D, Guay J, Weech PK, Laliberte F, Yergey J, Li C, et al. Arachidonyl trifluoromethyl ketone, a potent inhibitor of 85-kDa phospholipase A2, blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. J Biol Chem. 1994;269:15619–24.PubMed
39.
Ackermann EJ, Conde-Frieboes K, Dennis EA. Inhibition of macrophage Ca(2+)-independent phospholipase A2 by bromoenol lactone and trifluoromethyl ketones. J Biol Chem. 1995;270:445–50.CrossRefPubMed
40.
Myou S, Sano H, Fujimura M, Zhu X, Kurashima K, Kita T, et al. Blockade of eosinophil migration and airway hyperresponsiveness by cPLA2-inhibition. Nat Immunol. 2001;2:145–9.CrossRefPubMed
41.
Nagase T, Uozumi N, Aoki-Nagase T, Terawaki K, Ishii S, Tomita T, et al. A potent inhibitor of cytosolic phospholipase A2, arachidonyl trifluoromethyl ketone, attenuates LPS-induced lung injury in mice. Am J Physiol Lung Cell Mol Physiol. 2003;284:L720–6.CrossRefPubMed
42.
Kalyvas A, David S. Cytosolic phospholipase A2 plays a key role in the pathogenesis of multiple sclerosis-like disease. Neuron. 2004;41:323–35.CrossRefPubMed
43.
Magrioti V, Kokotos G. Phospholipase A2 inhibitors as potential therapeutic agents for the treatment of inflammatory diseases. Expert Opin Ther Pat. 2010;20:1–18.CrossRefPubMed
44.
Watanabe K, Konno S, Sekiguchi M, Kikuchi S. Spinal stenosis: assessment of motor function, VEGF expression and angiogenesis in an experimental model in the rat. Eur Spine J. 2007;16:1913–8.CrossRefPubMedCentralPubMed
45.
Khan M, Im YB, Shunmugavel A, Gilg AG, Dhindsa RK, Singh AK, et al. Administration of S-nitrosoglutathione after traumatic brain injury protects the neurovascular unit and reduces secondary injury in a rat model of controlled cortical impact. J Neuroinflammation. 2009;6:32.CrossRefPubMedCentralPubMed
46.
Randall LO, Selitto JJ. A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther. 1957;111:409–19.PubMed
47.
Khan M, Singh J, Singh I. Plasmalogen deficiency in cerebral adrenoleukodystrophy and its modulation by lovastatin. J Neurochem. 2008;106:1766–79.PubMedCentralPubMed
48.
Khan M, Contreras M, Singh I. Endotoxin-induced alterations of lipid and fatty acid compositions in rat liver peroxisomes. J Endotoxin Res. 2000;6:41–50.CrossRefPubMed
49.
Weerheim AM, Kolb AM, Sturk A, Nieuwland R. Phospholipid composition of cell-derived microparticles determined by one-dimensional high-performance thin-layer chromatography. Anal Biochem. 2002;302:191–8.CrossRefPubMed
50.
Yonetake T, Sekiguchi M, Konno S, Kikuchi S, Kanaya F. Compensatory neovascularization after cauda equina compression in rats. Spine (Phila Pa 1976). 2008;33:140–5.CrossRef
51.
Shunmugavel A, Martin MM, Khan M, Copay AG, Subach BR, Schuler TC, et al. Simvastatin ameliorates cauda equina compression injury in a rat model of lumbar spinal stenosis. J Neuroimmune Pharmacol. 2013;8:274–86.CrossRefPubMedCentralPubMed
52.
Biyani A, Andersson GB. Low back pain: pathophysiology and management. J Am Acad Orthop Surg. 2004;12:106–15.PubMed
53.
Jaggi AS, Jain V, Singh N. Animal models of neuropathic pain. Fundam Clin Pharmacol. 2011;25:1–28.CrossRefPubMed
54.
David S, Greenhalgh AD, Lopez-Vales R. Role of phospholipase A2s and lipid mediators in secondary damage after spinal cord injury. Cell Tissue Res. 2012;349:249–67.CrossRefPubMed
55.
Lucas KK, Svensson CI, Hua XY, Yaksh TL, Dennis EA. Spinal phospholipase A2 in inflammatory hyperalgesia: role of group IVA cPLA2. Br J Pharmacol. 2005;144:940–52.CrossRefPubMedCentralPubMed
56.
Zhang J, Barasch N, Li RC, Sapirstein A. Inhibition of cytosolic phospholipase A(2) alpha protects against focal ischemic brain damage in mice. Brain Res. 2012;1471:129–37.CrossRefPubMed
57.
Sanchez-Mejia RO, Newman JW, Toh S, Yu GQ, Zhou Y, Halabisky B, et al. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer’s disease. Nat Neurosci. 2008;11:1311–8.CrossRefPubMedCentralPubMed
58.
Leis HJ, Windischhofer W. Inhibition of cyclooxygenases 1 and 2 by the phospholipase-blocker, arachidonyl trifluoromethyl ketone. Br J Pharmacol. 2008;155:731–7.CrossRefPubMedCentralPubMed
59.
Kunori S, Matsumura S, Okuda-Ashitaka E, Katano T, Audoly LP, Urade Y, et al. A novel role of prostaglandin E2 in neuropathic pain: blockade of microglial migration in the spinal cord. Glia. 2011;59:208–18.CrossRefPubMed
60.
Noguchi K, Okubo M. Leukotrienes in nociceptive pathway and neuropathic/inflammatory pain. Biol Pharm Bull. 2011;34:1163–9.CrossRefPubMed
61.
Moreland DB, Soloniuk DS, Feldman MJ. Leukotrienes in experimental spinal cord injury. Surg Neurol. 1989;31:277–80.CrossRefPubMed
62.
Iadecola C, Gorelick PB. The Janus face of cyclooxygenase-2 in ischemic stroke: shifting toward downstream targets. Stroke. 2005;36:182–5.CrossRefPubMed
63.
Davies NM, Jamali F. COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. J Pharm Pharm Sci. 2004;7:332–6.PubMed
64.
Sevastou I, Kaffe E, Mouratis MA, Aidinis V. Lysoglycerophospholipids in chronic inflammatory disorders: the PLA(2)/LPC and ATX/LPA axes. Biochim Biophys Acta. 2013;1831:42–60.CrossRefPubMed
65.
Sun GY, Xu J, Jensen MD, Simonyi A. Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. J Lipid Res. 2004;45:205–13.CrossRefPubMed
66.
Yung YC, Stoddard NC, Chun J. LPA receptor signaling: pharmacology, physiology, and pathophysiology. J Lipid Res. 2014;55:1192–214.CrossRefPubMed
67.
Inoue M, Xie W, Matsushita Y, Chun J, Aoki J, Ueda H. Lysophosphatidylcholine induces neuropathic pain through an action of autotaxin to generate lysophosphatidic acid. Neuroscience. 2008;152:296–8.CrossRefPubMed
68.
Ma L, Uchida H, Nagai J, Inoue M, Aoki J, Ueda H. Evidence for de novo synthesis of lysophosphatidic acid in the spinal cord through phospholipase A2 and autotaxin in nerve injury-induced neuropathic pain. J Pharmacol Exp Ther. 2010;333:540–6.CrossRefPubMed
69.
Nagai J, Uchida H, Matsushita Y, Yano R, Ueda M, Niwa M, et al. Autotaxin and lysophosphatidic acid1 receptor-mediated demyelination of dorsal root fibers by sciatic nerve injury and intrathecal lysophosphatidylcholine. Mol Pain. 2010;6:78.CrossRefPubMedCentralPubMed
70.
Shunmugavel A, Khan M, Martin MM, Copay AG, Subach BR, Schuler TC, et al. S-Nitrosoglutathione administration ameliorates cauda equina compression injury in rats. Neurosci Med. 2012;3:294–305.CrossRefPubMedCentralPubMed
71.
Glennie RA, Urquhart JC, Staudt MD, Lawendy AR, Gurr KR, Bailey CS. The relationship between the duration of acute cauda equina compression and functional outcomes in a rat model. Spine (Phila Pa 1976). 2014;39:E1123–31.CrossRef
Metadata
Title
Oral administration of cytosolic PLA2 inhibitor arachidonyl trifluoromethyl ketone ameliorates cauda equina compression injury in rats
Authors
Mushfiquddin Khan
Anandakumar Shunmugavel
Tajinder S Dhammu
Fumiyo Matsuda
Avtar K Singh
Inderjit Singh
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2015
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/s12974-015-0311-y

Other articles of this Issue 1/2015

Journal of Neuroinflammation 1/2015 Go to the issue

Research

Differential expression and clinical significance of three inflammation-related microRNAs in gangliogliomas

Research

Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation

Research

Altered morphological dynamics of activated microglia after induction of status epilepticus

Research

Trazodone regulates neurotrophic/growth factors, mitogen-activated protein kinases and lactate release in human primary astrocytes

Research

Microglia processes associate with diffusely injured axons following mild traumatic brain injury in the micro pig

Short report

Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype